A Clinicopathologic Study of Ovarian Granulosa Cell Tumor.
- Author:
Hyun Tae PARK
1
;
Ok Kyong KIM
;
Geum Joon CHO
;
Ki Hoon AHN
;
Nak Woo LEE
;
Tak KIM
;
Kyu Wan LEE
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Korea University, Seoul, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Granulosa cell tumor;
Ovary;
Prognostic factor
- MeSH:
Disease-Free Survival;
Female;
Follow-Up Studies;
Granulosa Cell Tumor*;
Granulosa Cells*;
Gynecology;
Hospital Records;
Humans;
Korea;
Obstetrics;
Ovary;
Prognosis;
Recurrence;
Retrospective Studies;
Rupture;
Telephone;
Uterine Hemorrhage
- From:Korean Journal of Obstetrics and Gynecology
2004;47(8):1505-1512
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The goal of this clinical study was to evaluate clinical and pathological findings, surgical procedures, and postoperative treatment in women with ovarian granulosa cell tumor. METHODS: A clinical study was made on 28 cases of ovarian granulosa cell tumor that were treated at the department of Obstetrics and Gynecology in Korea University Hospital between January 1978 and December 2002. Data for 28 women with granulosa cell tumor were collected retrospectively. Follow-up data were collected from the hospital records or telephone survey. Fisher's exact test and Kaplan-Meier survival analysis were applied, as appropriate. RESULTS: The mean age of patients was 49 years (range, 28 to 71 years). The most common present symptom was vaginal bleeding (11/28, 39.3%). 82.6% of patients were with FIGO stage I, 3.6% with stage II, 7.1% with stage III, and none with stage IV. Follow-up time was 62 months (5-128 months). The five year disease free survival rate was 90.4% and 10 year disease free survival rate was 86.5%. Significant prognostic factors were FIGO stage and the rupture of tumor. CONCLUSION: Even though granulosa cell tumor usually has good prognosis, it is a tumor of unquestionable malignant potential and has a tendency for late relapse. Long term follow-up is recommended. Multicenter prospective randomized studies are needed to identify the more rational treatment strategies of these rare malignant tumors.
